Skip to main content

MedPath Trial Home

Organizations News Research

Data Sources:ClinicalTrials.govEU CTRFDAEMANMPATGAHealth CanadaWHO ICTRP

MedPath Trial Home

Search trials. Track pipelines. Understand approvals. With AI-powered intelligence for clinical research.

Product

Clinical Trials
Drug Intelligence
Global Approvals
AI Research
Pricing

Resources

FAQ
Search

Company

News
About
Contact

Legal

Privacy Policy
Terms of Service

Disclaimer: This website provides information retrieval and data analysis services. The content does not constitute medical advice. Eligibility assessments are for reference only and should not replace consultation with qualified healthcare professionals. Data is sourced from public registries and regulatory agencies; MedPath does not guarantee completeness or accuracy. Always verify information with primary sources.

© 2026 MedPath Trial. All rights reserved.

We value your privacy

We use cookies to analyze site traffic and improve your experience. See our Privacy Policy.

CMC Contrast AB

Home Clinical Trial Sponsors and OrganizationsCMC Contrast AB

CMC Contrast AB

ACTIVE

Swedenwww.cmccontrast.comPrivate1–10 employeesEstablished: 2000-01-01

Part of Ascelia Pharma AB

Share to Twitter Share to Facebook Share to LinkedIn Share to Reddit

Clinical Trials

4

4 active

Approvals

0

Total approvals

Agencies

0

Regulatory bodies

Founded

2000

Overview

Trial Phase Distribution

No trial phase data available

Trial Status Distribution

Active, not recruiting

4

100.0%

Clinical Trials

Trials sponsored by this organization (4)

Comparison of an oral and an injectable contrast agent for Magnetic Resonance Imaging used for diagnosis of liver lesions in diagnosed cancer patients.

Active, not recruiting

Evaluation of the imaging quality of CMC-001(manganese chloride tetrahydrate) in liver Magnetic Resonance Imaging (MRI) in healthy volunteers. A double-blind, randomized cross-over, dose-response study

Active, not recruiting

Evaluation of the diagnostic efficacy of CMC-001 (manganese chloride tetrahydrate) in liver MR-imaging in patients with liver metastases. A randomised, parallel group, open-label Phase II trial.

Active, not recruiting

Evaluation of the diagnostic quality of CMC-001 (manganese chloride tetrahydrate) in liver MR-imaging in patients with liver metastases in comparison to Gadolinium BOPTA. A randomised cross-over Phase III Trial.

Active, not recruiting

Approvals

No approval data available

News

No news articles found

On this page

Overview
Clinical Trials4
Approvals
News

Back to Organizations